Found: 12
Select item for more details and to access through your institution.
Two-Drug Regimens Dolutegravir/Lamivudine and Dolutegravir/Rilpivirine Are Effective with Few Discontinuations in US Real-World Settings: Results from the TANDEM Study.
- Published in:
- Infectious Diseases & Therapy, 2024, v. 13, n. 4, p. 891, doi. 10.1007/s40121-024-00961-y
- By:
- Publication type:
- Article
Pharmacokinetics of Etravirine Combined with Atazanavir/Ritonavir and a Nucleoside Reverse Transcriptase Inhibitor in Antiretroviral Treatment-Experienced, HIV-1-Infected Patients.
- Published in:
- AIDS Research & Treatment, 2015, v. 2015, p. 1, doi. 10.1155/2015/938628
- By:
- Publication type:
- Article
Factors Associated with Health Care Providers' Preference for Forgoing an Oral Lead-In Phase When Initiating Long-Acting Injectable Cabotegravir and Rilpivirine in the SOLAR Clinical Trial.
- Published in:
- AIDS Patient Care & STDs, 2023, v. 37, n. 1, p. 53, doi. 10.1089/apc.2022.0168
- By:
- Publication type:
- Article
Overall safety profile of boceprevir plus peginterferon alfa-2b and ribavirin in patients with chronic hepatitis C genotype 1: a combined analysis of 3 phase 2/3 clinical trials.
- Published in:
- Liver International, 2014, v. 34, n. 5, p. 707, doi. 10.1111/liv.12300
- By:
- Publication type:
- Article
Evaluation of cardiovascular biomarkers in a randomized trial of fosamprenavir/ritonavir vs. efavirenz with abacavir/lamivudine in underrepresented, antiretroviral-naïve, HIV-infected patients (SUPPORT): 96-week results.
- Published in:
- BMC Infectious Diseases, 2013, v. 13, n. 1, p. 1, doi. 10.1186/1471-2334-13-269
- By:
- Publication type:
- Article
Evaluation of cardiovascular biomarkers in a randomized trial of fosamprenavir/ritonavir vs. efavirenz with abacavir/lamivudine in underrepresented, antiretroviral-naïve, HIV-infected patients (SUPPORT): 96-week results.
- Published in:
- 2013
- By:
- Publication type:
- journal article
Durability of sustained virological response to glecaprevir/pibrentasvir and resistance development: A long‐term follow‐up study.
- Published in:
- Liver International, 2022, v. 42, n. 6, p. 1278, doi. 10.1111/liv.15211
- By:
- Publication type:
- Article
A Phase IIa Study Evaluating Safety, Pharmacokinetics, and Antiviral Activity of GSK2838232, a Novel, Second-generation Maturation Inhibitor, in Participants With Human Immunodeficiency Virus Type 1 Infection.
- Published in:
- Clinical Infectious Diseases, 2020, v. 71, n. 5, p. 1255, doi. 10.1093/cid/ciz938
- By:
- Publication type:
- Article
Phase IIa Proof-of-Concept Evaluation of the Antiviral Efficacy, Safety, Tolerability, and Pharmacokinetics of the Next-Generation Maturation Inhibitor GSK3640254.
- Published in:
- Clinical Infectious Diseases, 2022, v. 75, n. 5, p. 786, doi. 10.1093/cid/ciab1065
- By:
- Publication type:
- Article
THIGH INJECTIONS OF CABOTEGRAVIR+RILPIVIRINE IN VIRALLY SUPPRESSED ADULTS WITH HIV-1.
- Published in:
- Topics in Antiviral Medicine, 2023, v. 31, n. 2, p. 204
- By:
- Publication type:
- Article
Long‐term safety and efficacy results in hepatitis C virus genotype 1‒infected patients receiving ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin in the TOPAZ‐I and TOPAZ‐II trials.
- Published in:
- Journal of Viral Hepatitis, 2020, v. 27, n. 5, p. 497, doi. 10.1111/jvh.13261
- By:
- Publication type:
- Article
Pharmacokinetics and antiviral activity of cabotegravir and rilpivirine in cerebrospinal fluid following long-acting injectable administration in HIV-infected adults.
- Published in:
- 2020
- By:
- Publication type:
- journal article